Altrenogest (Regu-Mate)

Altrenogest is a synthetic progestogen specifically developed for veterinary use in reproductive management of horses and swine. Chemically related to natural progesterone, altrenogest mimics the physiological effects of progesterone on the reproductive system while offering improved oral bioavailability and consistent pharmacological activity that natural progesterone lacks when given by mouth. The drug has become an essential tool in equine reproduction programs and commercial swine production, where precise control of the estrous cycle provides significant management and economic benefits.

The mechanism of action of altrenogest involves binding to progesterone receptors in the hypothalamus, pituitary, and reproductive tract, creating a hormonal environment that simulates the luteal phase of the estrous cycle. By providing exogenous progestational support, altrenogest suppresses gonadotropin-releasing hormone secretion from the hypothalamus and reduces pituitary release of follicle-stimulating hormone and luteinizing hormone. This negative feedback suppresses follicular development and ovulation, maintaining the animal in a state of reproductive quiescence similar to that which occurs naturally during the luteal phase or pregnancy. When altrenogest administration ceases, the removal of progestational inhibition allows the hypothalamic-pituitary-gonadal axis to resume normal cyclic activity.

Altrenogest for livestock use is available as an oral oil-based solution standardized to 0.22% concentration, marketed as Regu-Mate for horses and Matrix for swine. The oil formulation provides a stable vehicle for the lipophilic compound and facilitates absorption from the gastrointestinal tract. Administration is typically by top-dressing on feed or by direct oral dosing, depending on the management situation. The consistent oral bioavailability of altrenogest distinguishes it from natural progesterone, which is largely inactivated during first-pass hepatic metabolism when given orally. Daily administration is required to maintain effective progestational activity, as the drug is metabolized and eliminated within hours of each dose.

The regulatory status of altrenogest reflects its established role in specific reproductive management applications while imposing important restrictions on use. In the United States, altrenogest is FDA-approved for use in horses and swine only, with explicit prohibitions against use in other food-producing species. The drug is not approved for use in horses intended for food and carries a specific prohibition against use in cattle, sheep, and goats. Prescription status requires a valid veterinarian-client-patient relationship for all uses. The stringent human safety warnings associated with altrenogest reflect the potent progestational activity and the risks of absorption through skin contact.

The primary labeled indication for altrenogest in horses is suppression and control of estrus in mares for management purposes. Many mares exhibit behavioral changes during estrus that interfere with training, competition, or work activities, including irritability, resistance to handling, decreased appetite, and distraction. Altrenogest administration suppresses the behavioral manifestations of estrus by maintaining progestational dominance, allowing mares to perform without the interruptions and challenges associated with their natural reproductive cycle. This application has become particularly important in competitive equestrian disciplines where consistent behavior and performance are essential.

Estrus synchronization represents another major indication for altrenogest, where the drug is used to coordinate the reproductive cycles of groups of mares or gilts for breeding management purposes. By administering altrenogest to a group of cycling females simultaneously and withdrawing treatment at the same time, producers can achieve synchronized return to estrus that facilitates artificial insemination programs, embryo transfer scheduling, or natural breeding coordination. The predictable timing of estrus following altrenogest withdrawal allows efficient scheduling of breeding activities and reduces the labor required for estrus detection across large groups.

In swine production, altrenogest is approved for estrus synchronization in sexually mature gilts, where it provides a tool for batch farrowing management systems. By synchronizing estrus across groups of gilts, producers can implement all-in-all-out production flows that improve biosecurity, facilitate efficient facility utilization, and standardize pig ages within groups. The predictable return to estrus following altrenogest withdrawal allows scheduling of artificial insemination and improves conception rates by ensuring proper timing of breeding. This application has become integral to modern commercial swine production systems.

Pregnancy maintenance support represents an extra-label but widely practiced application of altrenogest in mares with history of pregnancy loss or documented luteal insufficiency. Mares that have experienced early embryonic death or abortion may benefit from progestational support during the critical early pregnancy period before the placenta assumes progesterone production. Altrenogest supplementation can help maintain pregnancy in mares with inadequate endogenous progesterone production, particularly those with compromised luteal function. This application requires careful veterinary oversight and monitoring to optimize treatment protocols for individual patients.

Extra-label applications of altrenogest beyond the approved indications in horses and swine are generally prohibited in food-producing animals due to the lack of established withdrawal times and food safety data. Use in cattle, sheep, and goats is specifically prohibited under FDA regulations. However, within the approved species, veterinary judgment may guide applications beyond strict label indications, such as management of granulosa cell tumors in mares or specialized breeding management scenarios. Any extra-label use requires thorough veterinary evaluation and appropriate client communication regarding off-label status.

Dosing of altrenogest is species-specific and standardized based on established efficacy data. In horses, the approved dose is 0.044 mg per kilogram body weight daily, which translates to 1 mL of Regu-Mate per 50 pounds body weight. For a typical 1,000-pound mare, this equates to approximately 10 mL of the 0.22% solution daily. The dose should be administered consistently at the same time each day to maintain steady progestational activity. Treatment duration for estrus suppression is typically 15 days minimum, with continued treatment as long as suppression is desired. For estrus synchronization, treatment duration is typically 14 to 15 days followed by withdrawal to induce synchronized return to estrus.

In swine, the approved dosing for Matrix is 15 mg per gilt per day for 14 consecutive days. This dose is delivered through 6.8 mL of the 0.22% solution, typically administered by top-dressing on a small amount of feed to ensure complete consumption. For optimal results, each gilt should consume her full dose, which may require individual feeding or careful observation during group feeding situations. Treatment should begin when gilts are cycling and should be administered consistently for the full 14-day period to achieve effective synchronization. Estrus is expected to occur 4 to 9 days after the last treatment.

The route of administration for altrenogest is exclusively oral, with the oil-based solution designed for top-dressing on feed or direct oral administration. In horses, the product may be administered by syringe directly into the mouth, by top-dressing on grain, or by mixing with a small amount of palatable feed. Care must be taken to ensure complete dose consumption, as incomplete intake reduces efficacy. In swine, top-dressing on feed is the standard administration method, with individual gilt feeding preferred to ensure accurate dosing. The oil vehicle should not be diluted or mixed with large volumes of feed that might result in incomplete consumption.

Treatment duration varies by indication, with estrus suppression in mares requiring ongoing daily treatment for as long as suppression is desired. For synchronization purposes, treatment duration is fixed at 14 to 15 days to effectively suppress the cycle before coordinated withdrawal. Consistency of daily dosing is essential for maintaining effective progestational activity, as missed doses can result in breakthrough follicular development and unexpected estrus. For pregnancy maintenance applications, treatment duration extends through the period of risk for pregnancy loss, typically through day 100 to 120 of gestation when placental progesterone production is well established.

Administration technique requires particular attention to human safety given the significant absorption risk through skin contact. Handlers should wear protective gloves and avoid any skin exposure to the product. Women of childbearing age should not handle altrenogest due to the risk of absorption causing reproductive effects. Pregnant women must not handle the product under any circumstances. Administration should be conducted in a manner that minimizes spillage and exposure, and any skin contact should be immediately addressed by washing with soap and water. The human safety concerns associated with altrenogest are more significant than for most veterinary pharmaceuticals.

Withdrawal times for altrenogest must be observed when treated animals are intended for food use. In swine, the withdrawal period is 21 days after the last treatment. Horses treated with Regu-Mate should not be slaughtered for human consumption, as the product is not approved for food-producing horses. The withdrawal period in swine is critical for ensuring that drug residues have cleared to safe levels before slaughter, and accurate record-keeping of treatment dates is essential for compliance verification. Altrenogest is not approved for use in cattle, sheep, goats, or other food animals, and its use in these species is prohibited.

Altrenogest demonstrates acceptable tolerability in both horses and swine when administered according to label directions, with the progestational effects representing the expected pharmacological activity rather than adverse reactions. The primary observable effects of altrenogest treatment relate to reproductive system suppression, including absence of estrus behavior and cessation of ovarian cyclic activity. These effects are the intended therapeutic outcomes and reverse upon treatment discontinuation. The consistent pharmacological profile of altrenogest reflects its specific receptor-mediated mechanism of action.

Common side effects observed in horses receiving altrenogest are generally limited to the expected reproductive effects. Some mares may show changes in temperament or behavior during treatment, though these effects are variable and may be positive in mares where estrus-related behavior problems were the indication for treatment. Occasional reports of decreased appetite or mild gastrointestinal upset have been associated with the oral oil formulation, though these effects are uncommon. The prolonged suppression of ovarian activity during extended treatment periods is a physiological effect rather than a side effect per se, and normal cyclic activity typically resumes promptly after treatment cessation.

In swine, side effects of altrenogest treatment are similarly limited to the expected effects on the reproductive system. Gilts receiving treatment for estrus synchronization demonstrate suppressed estrus behavior and ovarian activity during the treatment period, with return to estrus following withdrawal. The consistency of response in swine reflects the well-characterized pharmacology of the compound. Individual variation in response time to estrus after treatment withdrawal occurs and should be anticipated in synchronization program planning.

Serious adverse effects from altrenogest in treated animals are uncommon when the drug is used according to label directions. Prolonged or repeated treatment periods have been associated with uterine pathology in some mares, including accumulation of uterine fluid and development of endometrial conditions, though these effects are variable and their relationship to treatment is not always clear. Anecdotal reports of systemic effects have included lethargy or behavioral changes in some horses, though controlled studies have not consistently demonstrated significant systemic toxicity at therapeutic doses.

Species-specific considerations emphasize that altrenogest is approved only for horses and swine, and use in other species carries unknown risks. The prohibition against use in cattle, sheep, and goats reflects both the lack of safety data in these species and food safety concerns related to undefined withdrawal periods. In approved species, the effects of altrenogest on reproduction are reversible, with normal fertility expected after treatment discontinuation. However, the timing of return to fertility may be influenced by the duration of treatment and individual animal variation in response to progestational withdrawal.

Species restrictions represent the most fundamental contraindications for altrenogest, with the drug approved only for horses and swine and explicitly prohibited in other food-producing species. Use in cattle, sheep, and goats is specifically prohibited by FDA regulation, reflecting both the lack of established safety data and concerns about drug residues in food products from these species. Horses intended for food are similarly excluded from altrenogest use, as Regu-Mate is not approved for food-producing horses. These species restrictions are absolute and non-negotiable regardless of the clinical situation or management goals.

Production stage restrictions apply to the specific reproductive status of animals receiving altrenogest. In horses, the drug is contraindicated for use in stallions and in pregnant mares except when specifically indicated for pregnancy maintenance under veterinary supervision. Administration to pregnant mares without a clear medical indication could interfere with normal pregnancy physiology. In swine, Matrix is approved specifically for sexually mature gilts and is not indicated for use in boars, immature gilts, or pregnant sows. These restrictions ensure appropriate use within the validated clinical contexts.

Age and reproductive development restrictions determine eligibility for altrenogest treatment. In both horses and swine, the drug is intended for use in sexually mature animals with established cyclic reproductive activity. Prepubertal animals should not receive altrenogest, as the drug's effects on the immature reproductive system have not been characterized. In horses, treatment of fillies before the establishment of normal cyclic activity is not appropriate. Similarly, gilts must be sexually mature before treatment for estrus synchronization can be effective.

Disease state contraindications for altrenogest include any conditions that could be exacerbated by progestational hormone activity or that represent underlying causes of reproductive dysfunction that should be addressed rather than masked. Mares with uterine pathology including endometritis or significant uterine fluid accumulation may not be appropriate candidates for altrenogest treatment until these conditions are resolved. Reproductive tract abnormalities, hormonal disorders, and infectious conditions affecting the reproductive system require proper diagnosis and treatment rather than management with progestational suppression. The use of altrenogest to manage behavioral problems should be preceded by evaluation for underlying physical causes of the behavior.

Important drug class interactions with altrenogest are relatively limited given the hormone's specific receptor-mediated mechanism and the contexts in which it is typically used. Concurrent use with other hormonal agents affecting the reproductive axis requires consideration of the combined effects on reproductive function. Prostaglandins including dinoprost and cloprostenol are sometimes used in combination with altrenogest to lyse any existing corpus luteum before initiating synchronization treatment, though this is a managed combined use rather than a problematic interaction. The sequential relationship between altrenogest withdrawal and subsequent breeding protocol medications is a planned therapeutic strategy.

Anti-progestational agents would theoretically antagonize the effects of altrenogest, though such interactions are not typically encountered in veterinary practice. Mifepristone and related compounds that block progesterone receptors could reduce the efficacy of altrenogest, but these drugs are not commonly used in equine or swine practice. The more practical concern is ensuring that altrenogest is not inadvertently combined with other progestational products that could result in excessive progestational activity, though such combinations are rarely indicated.

Feed additive interactions with altrenogest in swine require consideration of the oral administration route and potential effects on absorption. Medications mixed with feed should be separated from altrenogest administration to ensure complete consumption of the progestin dose without dilution. Ionophores and other feed additives do not have direct pharmacological interactions with altrenogest but should be managed separately in feeding protocols. The oil-based altrenogest solution should be top-dressed on a controlled amount of feed to ensure complete dose consumption before other feeds or additives are offered.

Vaccine interactions with altrenogest are not documented, and no direct pharmacological interference between progestins and vaccine immune responses is expected. However, the reproductive management protocols that incorporate altrenogest treatment often coincide with other management events including vaccination schedules. Coordination of these activities for efficient animal handling is a practical consideration rather than a concern about drug interaction. The immunological effects of progestational hormones are modest and not expected to significantly affect vaccine efficacy at therapeutic doses.

Human safety considerations for altrenogest are more significant than for most veterinary pharmaceuticals and require particular emphasis. The drug is readily absorbed through skin contact, and exposure can cause serious reproductive effects in humans. Women of childbearing age should not handle altrenogest, and pregnant women must not handle the product under any circumstances due to the risk of disruption of pregnancy or contraceptive efficacy. Skin contact should be avoided absolutely, and protective gloves must be worn during product handling and administration. In case of accidental skin exposure, the affected area should be washed immediately with soap and water.

Additional human safety warnings address the risks of spillage and exposure during administration. The product should be handled carefully to avoid splashing or dripping during dosing. Any spills should be cleaned immediately while wearing protective gloves. Handlers should not eat, drink, or smoke while handling the product to prevent inadvertent ingestion. The product container should be stored securely to prevent access by children or unprotected adults. These extensive human safety precautions reflect the potent hormonal activity of altrenogest and its high absorption potential through multiple exposure routes.

Food safety considerations for altrenogest center on the strict limitations on species in which the drug may be used and the withdrawal requirements in swine. The prohibition against use in cattle, sheep, and goats reflects unacceptable risk of drug residues in food products from these species. In swine, the 21-day withdrawal period must be rigorously observed to ensure residues have declined to safe levels before slaughter. Record-keeping must accurately document treatment dates and animal identification to verify withdrawal compliance. Horses treated with Regu-Mate should not be slaughtered for human consumption regardless of time elapsed since treatment.

Animal welfare considerations for altrenogest use include recognition of the effects of prolonged reproductive suppression and the importance of appropriate indication for treatment. While estrus suppression serves legitimate management purposes in many horses, prolonged treatment without clear indication raises questions about necessity. The reversibility of altrenogest effects supports its safety for temporary reproductive management, but long-term implications of extended treatment on reproductive tract health warrant ongoing evaluation. Treatment decisions should be based on genuine management needs rather than convenience.

Proper use guidelines for altrenogest emphasize the importance of accurate dosing, consistent daily administration, and appropriate treatment duration for the specific indication. The drug should be used under veterinary supervision with clear treatment goals and endpoints. Documentation of treatment supports both regulatory compliance and medical record-keeping. The significant human safety concerns require that product handling procedures be established and followed consistently, with training for all personnel involved in administration.

Storage requirements for altrenogest specify protection from conditions that could compromise product stability. The oil-based solution should be stored at controlled room temperature, typically 15°C to 30°C (59°F to 86°F), protected from light and excessive heat. The product should not be frozen, as this could affect the formulation characteristics. The container should be kept tightly closed when not in use to prevent contamination and evaporation. Storage should be in a secure location to prevent access by children or unauthorized individuals, and the human safety warnings on the product should be clearly visible.

Handling of altrenogest requires exceptional attention to human safety due to the significant absorption risk through skin contact. Protective gloves must be worn whenever handling the product, including during storage, transfer, or administration. The person opening the container should take care to avoid splashing or dripping of the oil solution. Measuring devices should be handled carefully and cleaned or disposed of appropriately after use. Any spills should be cleaned immediately while wearing protective gloves, and contaminated materials should be disposed of safely.

Disposal of altrenogest products requires attention to both pharmaceutical waste regulations and the human safety concerns associated with the compound. Unused or expired product should not be disposed of through regular trash or wastewater systems where exposure risks could occur. Pharmaceutical waste disposal services or return programs provide appropriate disposal pathways. Contaminated materials including gloves, paper towels, and measuring devices should be disposed of safely to prevent inadvertent human exposure. Empty containers should be disposed of according to applicable regulations, with attention to preventing contact with any residual product.

Species-specific dosing considerations for altrenogest reflect the established dosing regimens for horses and swine, the only approved species. In horses, the dose of 0.044 mg/kg daily is applied consistently across breeds and types, from ponies to draft horses, with the volume administered adjusted proportionally to body weight. The consistent receptor-mediated mechanism of action supports this weight-based approach across the wide range of equine body sizes. In swine, the fixed 15 mg daily dose for gilts reflects the more uniform body size range in commercial swine genetics and the specific synchronization application.

Breed sensitivities to altrenogest have not been documented as significant concerns in either horses or swine. Within the equine species, various breeds including Thoroughbreds, Warmbloods, Quarter Horses, and Arabian horses have been successfully treated with altrenogest for estrus suppression and synchronization without breed-specific adverse effects. The pharmacology of progestational hormones is conserved across breeds, supporting consistent response expectations. In swine, commercial breeding programs utilize altrenogest across various genetic lines without documented breed-specific considerations.

Production type considerations influence altrenogest use primarily in the context of food animal regulations and intended animal use. In horses, the distinction between performance horses and horses potentially destined for food use determines product eligibility, as Regu-Mate is not approved for food-producing horses. In swine, the 21-day withdrawal period applies regardless of production system, and gilts treated with Matrix must be withdrawn from treatment for appropriate duration before slaughter. The drug's exclusion from use in cattle, sheep, and goats eliminates consideration of production type variables in those species.

Age and reproductive maturity considerations are essential for appropriate altrenogest use. Both horses and swine must be sexually mature with established cyclic activity before treatment is indicated. In mares, this typically means treatment is appropriate after the filly has begun cycling, usually by 12 to 18 months of age, though treatment is more commonly initiated in mature mares where behavioral management is the indication. In gilts, sexual maturity with observed estrus cycles must be established before synchronization treatment can be effective. Prepubertal animals in either species should not receive altrenogest, as the reproductive system must be developed for the drug to produce its intended effects.

Same-class alternatives to altrenogest include other progestational agents used in reproductive management across species. Medroxyprogesterone acetate is a synthetic progestin with some veterinary applications, though it is not commonly used in horses or swine for the same indications as altrenogest. Melengestrol acetate is a progestational feed additive used in cattle for estrus suppression and growth promotion, though it represents a different product category and is not appropriate for horses or swine. Natural progesterone can be administered by injection, but its poor oral bioavailability makes it unsuitable for the management applications where altrenogest excels.

Different mechanism alternatives for reproductive management in horses include physical methods and other hormonal approaches. Intrauterine glass balls have been used in mares to suppress estrus through proposed mechanisms involving the endometrium, though efficacy is variable. GnRH vaccine products designed to suppress reproductive function through immune-mediated mechanisms represent another approach, though these have irreversible effects that may be undesirable in breeding animals. For estrus synchronization specifically, prostaglandin-based protocols provide an alternative to progestational approaches, though the timing and predictability differ.

Combination approaches using altrenogest with other hormonal agents are employed in comprehensive reproductive management protocols. In mare reproductive programs, altrenogest may be preceded by prostaglandin administration to lyse existing corpora lutea before initiating progestational treatment. Following altrenogest withdrawal, human chorionic gonadotropin or deslorelin may be administered to induce ovulation at a predictable time for breeding. These sequential combination protocols represent standard practice in advanced equine reproduction programs. In swine, altrenogest synchronization may be followed by gonadotropin administration to optimize ovulation timing in artificial insemination programs.